Investigating the effect of arachidonate supplementation on the phosphoinositide content of MCF10a breast epithelial cells  by Anderson, Karen E. et al.
Advances in Biological Regulation 62 (2016) 18e24Contents lists available at ScienceDirectAdvances in Biological Regulation
journal homepage: www.elsevier .com/locate/ jbiorInvestigating the effect of arachidonate supplementation on
the phosphoinositide content of MCF10a breast epithelial
cells
Karen E. Anderson a, Veronique Juvin a, Jonathan Clark b, Len R. Stephens a, *, 1,
Phillip T. Hawkins a, 1
a Inositide Laboratory and Babraham Institute, Babraham Research Campus, Babraham, Cambridge, CB223AT, UK
b Biological Chemistry Laboratory, Babraham Institute, Babraham Research Campus, Babraham, Cambridge CB223AT, UKa r t i c l e i n f o
Article history:
Received 1 October 2015
Accepted 5 November 2015







Clark), len.stephens@babraham.ac.uk (L.R. Stephens
1 Both authors contributed equally to this work.
http://dx.doi.org/10.1016/j.jbior.2015.11.002
2212-4926/© 2015 The Authors. Published by Elsevie
0/).a b s t r a c t
Phosphoinositides in primary mammalian tissue are highly enriched in a stearoyl/arach-
idonyl (C38:4) diacylgycerol backbone. However, mammalian cells grown in culture
typically contain more diverse molecular species of phosphoinositides, characterised by a
reduction in arachidonyl content in the sn-2 position. We have analysed the phosphoi-
nositide species in MCF10a cells grown in culture by mass spectrometry. Under either
serum or serum starved conditions the most abundant species of PI, PIP, PIP2 and PIP3 had
masses which corresponded to C36:2, C38:4, C38:3, C38:2 and C36:1 diacylglycerol
backbones and the relative proportions of each molecular species were broadly similar
between each phosphoinositide class (approx. 50%, 25%, 10%, 10% and 10% respectively, for
the species listed above). Supplementing the culture mediumwith BSA-loaded arachidonic
acid promoted a rapid increase in the proportion of the C38:4 species in all phosphoino-
sitide classes (from approx. 25%e60% of total species within 24 h), but the total amount of
all combined species for each class remained remarkably constant. Stimulation of cells,
cultured in either normal or arachidonate-enriched conditions, with 2 ng/ml EGF for 90 s
caused substantial activation of Class I PI3K and accumulation of PIP3. Despite the
increased proportion of C38:4 PIP3 under the arachidonate-supplemented conditions, the
total amount of all combined PIP3 species accumulating in response to EGF was the same,
with or without arachidonate supplementation; there were however small but signiﬁcant
preferences for the conversion of some PIP2 species to PIP3, with the polyunsaturated
C38:4 and C38:3 species being more favoured over other species. These results suggest the
enzymes which interconvert phosphoinositides are able to act on several different mo-
lecular species and homoeostatic mechanisms are in place to deliver similar phosphoi-
nositide pool sizes under quite different conditions of arachidonate availability. They also
suggest enzymes regulating PIP3 levels downstream of growth factor stimulation (i.e. PI3Ks
and PIP3-phosphatases) show some acyl selectivity and further work should be directed at
assessing whether different acyl species of PIP3 exhibit differing signalling potential.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/)..uk (K.E. Anderson), veronique.juvin@babraham.ac.uk (V. Juvin), jonathan.clark@babraham.ac.uk (J.
), phillip.hawkins@babraham.ac.uk (P.T. Hawkins).
r Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.
K.E. Anderson et al. / Advances in Biological Regulation 62 (2016) 18e24 191. Introduction
Phosphoinositides are a family of inositol-containing phospholipids that comprise eight different headgroups in higher
eukaryotes; PI, PI(3)P, PI(4)P, PI(5)P, PI(4,5)P2, PI(3,4)P2, PI(3,5)P2 and PI(3,4,5)P3 (PIP3) (see Fig. 1A) (Balla, 2013). They are
interconverted by kinases and phosphatases that add or remove mono-esteriﬁed phosphate groups on the inositol ring
(Fig. 2A) (Balla, 2013). They can also be metabolised by phospholipases A, C or D that remove acyl chains or inositolFig. 1. Phosphoinositide structures. A: The structure of stearoyl (C18:0), arachidonyl (C20:4) phosphatidylinositol, together with the bonds cleaved by phos-
pholipases A1, A2 and C. B: Cartoon structures for the phosphoinositides found in higher eukaryotes.
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shuttled between membranes by exchange proteins, but enzymes responsible for phosphorylation and dephosphorylation of
PI, PIPs and PIP2s exhibit widely different activities at different sub-cellular locations, leading towidely differing distributions
for the polyphosphorylated phosphoinositides themselves (Balla, 2013). The different phosphoinositides have been ascribed
multiple regulatory roles on the membranes in which they are found, and a common theme is that they act as regulatable
scaffolds that dictate the location and activity of effectors through the speciﬁc binding of their differentially phosphorylated
inositol head groups to conserved protein domains (Hammond and Balla, 2015; Lemmon, 2008). One of the best studied roles
for these lipids is the stimulated conversion of PI(4,5)P2 to PIP3 at the plasma membrane by growth factor receptor activation
of Class I PI3Ks (Fig. 2A) (Hawkins and Stephens, 2015; Vanhaesebroeck et al., 2010). PIP3 acts as a signal by co-ordinating the
activity of multiple effector proteins, which in turn regulate complex cellular responses such as cell growth and movement.
The best studied of these PIP3 effectors are PH-domain containing protein kinases (e.g. AKT, PDK1, BTK) and GEFs or GAPS for
small GTPases (e.g. P-REX, GRP-1, ARAP3) (Hawkins and Stephens, 2015; Vanhaesebroeck et al., 2010). Mutations driving
increased activity of Class I PI3K and/or decreased removal of PIP3 are amongst the most prevalent in a range of human
cancers, including EGF-receptor dependent transformation of breast epithelial cells (Wilks, 2015; Yap et al., 2015).
Individual classes of glycerophospholipids are deﬁned by the nature of the head group present, but they usually comprise a
surprisingly diverse range of molecular species that are differentiated by the nature of the hydrocarbon chains linked via acyl
or ether linkages to their glycerol backbone. The precise range of chains present is dictated both by the cell type and the head
group, but typically comprises more than 5e30 different species for one head group. In most cases the biological function of
this hydrocarbon diversity is unknown and is usually assumed to reside in the aggregate biophysical properties that the sum
total of these species convey to the membranes in which they reside, such as ﬂuidity or bilayer dimension. The phosphoi-
nositides are unusual amongst glycerophospholipids in that they have been found to bemuchmoremolecularly homogenous
than other analogous lipid classes; thus phosphoinositides in mammals are typically >80% stearoyl (C18:0)/arachidonylFig. 2. Pathways of phosphoinositide metabolism. A: Pathways for inter-conversion of phosphoinositides by lipid kinases and phosphatases. Enzyme activities
mentioned in the text are highlighted. B: A schematic illustration of the major pathways for de novo synthesis of phosphoinositides in higher eukaryotes. Enzyme
activities highlighted indicate points at which enrichment for C38:4 species may occur.
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evolutionary conserved function might be ascribed to this particular species that may relate to their signalling roles e.g.
movement within the plane of a bilayer, or the manner of head group presentation to effectors.
Although phosphoinositides found in primary mammalian tissue are largely the C38:4 species, several studies have
suggested cells grown in culture are deprived of arachidonate and contain a more molecularly diverse repertoire of acyl
chains (Clark et al., 2011; Rouzer et al., 2006). We sought to investigate the effect of enriching the culture medium of MCF10a
breast epithelial cells with arachidonate on the acyl chain composition of phosphoinositides and the quantity of PIP3 accu-
mulating upon activation of PI3K signalling by EGF.
2. Materials and methods
2.1. Materials
Trimethylsilyl-diazomethane (as a 2 M solution in hexanes), arachidonate, fatty acid free (FAF)- and endotoxin free- BSA
were from SigmaeAldrich. 1-heptadcanoyl-2-hexadecanoyl-sn-glycero-3-(phosphoinositol-3,4,5-trisphosphate) (C17:0/
C16:0-PI(3,4,5)P3, as a hepta-sodium salt) used as an internal standard for mass spectrometry (ISD), was made at the Bab-
raham Institute as previously described (Clark et al., 2011). All cell culture reagents were from Invitrogen, while all other
reagents, unless speciﬁed, were from Sigma.
2.2. Arachidonic acid preparation and supplementation
A solution of arachidonic acid (50mM) was prepared in 10 mMKOH, and degassed by freeze/thawing under vacuum three
times. This solution was then diluted 67.26 fold in Dulbecco's PBS supplemented with 0.862 mM fatty acid free-, essentially
endotoxin free- BSA, pH7.4 which had been similarly degassed, to give a stock concentration of 740 mM (50 ﬁnal). The ﬁnal
stock was aliquoted under argon and stored at 80 C. Immediately prior to use, aliquots were thawed and added to horse
serum (complete or charcoal stripped as required), then ﬁlter sterilized into appropriate MCF10a media (complete, or star-
vation media as indicated, see below) at a 1/50 ﬁnal dilution, before adding to cells in culture for indicated times. Final
supplement concentrations were 14.8 mM arachidonic acid and 17 mM BSA.
2.3. MCF10a culture
MCF10a (provided by Horizon Discovery (Cambridge, UK)) were maintained at 37 C, 5% CO2, in DMEM/F12 media,
supplemented with horse serum (5%, PAA), hydrocortisone (0.5 mg/ml), insulin (10 mg/ml), cholera toxin (0.1 mg/ml) and EGF
(2 ng/ml). When required, cells were starved in DMEM/F12 media supplemented with charcoal-stripped horse serum (1%,
PAA) hydrocortisone and cholera toxin. Early passages of cells were used (13e20).
For initial arachidonic acid loading time course,1 (8 and 12 h) and 0.8 (24 h) x 105 cells were plated to 3.5 cm tissue culture
dishes in complete media in the absence or presence of arachidonic acid supplementation and incubated for the indicated
times. For stimulation experiments,1105 cells were plated onto 3.5 cm tissue culture dishes and allowed to adhere for 8 h in
complete media. Cells were then incubated for a further 16 h in the absence or presence of arachidonic acid, followed by 6 h
starvation (in the absence or presence of arachidonic acid) where indicated. Cells were stimulated with EGF (2 ng/ml) for 90 s
at 37 C. Media was rapidly aspirated and 1 M HCl (0.5 ml, 4 C) added. Cells were scraped from the plates, collected and spun
(15,000 g, 5 min, 4 C) then supernatants removed. Pellets were then resuspended in H2O (170 ml) and quench mix (750 ml)
and extraction commenced as described below.
2.4. Mass spectrometry measurements of inositol lipids
Mass spectrometry was used to measure inositol lipid levels essentially as previously described (Clark et al., 2011), using a
QTRAP 4000 (AB Sciex) mass spectrometer and employing the lipid extraction and derivitization method described for
MCF10a cells, with the modiﬁcation that 10 ng C17:0/C16:0 PtdIns(3,4,5)P3 ISD was added to primary extracts and that ﬁnal
samples were dried in a speedvac concentrator rather than under N2. Measurements were conducted in duplicate per
experiment.
3. Results
Previous work in our laboratory has used HPLC-ESI mass spectrometry to detect the presence of multiple species of PI, PIP,
PIP2 and PIP3 in MCF10a cells gown under standard cell culture conditions (Clark et al., 2011; Kielkowska et al., 2014); our
current techniques do not allow us to differentiate between regio-isomers of the samemass e.g. PI(4)P vs PI(3)P vs PI(5)P. The
distribution of molecular species was found to be very similar between the different classes of phosphoinositide, thus the
most abundant species was C36:2, followed in decreasing order by C38:4, C36:1, C38:3 and C38:2 (Fig. 3).
We supplemented the culture medium with 17 mM BSA loaded with 14.8 mM arachidonate, to approximate the physio-
logical levels of arachidonate that might be anticipated to prevail in the extracellular milieu in vivo. Supplementation with
Fig. 3. The effect of arachidonate supplementation on the molecular species of phosphoinositides in MCF10a cells. The ﬁve major species of PIP3 (A), PIP2 (B), PIP
(C) and PI (D) present in MCF10a cells were quantiﬁed by HPLC-ESI mass spectrometry. Cells were incubated in complete medium with or without 14.7 mM
arachidonate for the indicated times, as described in the methods. Data is shown for each phosphoinositide species corrected for amount of C36:1 phosphati-
dylserine in the same sample (mean ± SEM, n ¼ 3). Insets show total combined species of phosphoinositides for each condition. aa ¼ arachidonate.
K.E. Anderson et al. / Advances in Biological Regulation 62 (2016) 18e2422arachidonate increased the proportion of C38:4 species of phosphoinositide from around 25%e50% within 8 h, rising to 60%
(after 24 h; Fig. 3). The relative increases in the C38:4 species were again very similar between phosphoinositide classes but,
importantly, the total sum of all molecular species measured for PI, PIP, PIP2 and PIP3 remained remarkably constant with or
without arachidonate supplementation (Fig. 3, insets).
We then investigated the impact of arachidonate supplementation on the amount and type of PIP3 species that accumulate
after activation of Class I PI3K by EGF. Stimulation with 2 ng/ml EGF for 90 s, following starvation, stimulated a very
similar rise in the total species of PIP3 which accumulate in the presence or absence of arachidonate supplementation
(Fig. 4A). A careful analysis of the relative proportions of PIP3 molecular species which accumulated compared to the PIP2
species present in the same cells, suggests the following rank order of preference for accumulation of PIP3:
C38:4 > C38:3 > C36:2 > C38:2 ¼ C36:1 (Fig. 4B). No equivalent distortion was seen for the relative levels of PIP2 species
compared to PIP species, or PIP species compared to PI species (Fig. 4C and D).4. Discussion and conclusions
The substantial effect of arachidonate supplementation to increase the proportion of C38:4 molecular species of phos-
phoinositides in MCF10a cells supports the idea that cells grown in relatively small amounts of horse or calf serum are
effectively arachidonate deprived (Rouzer et al., 2006). Arachidonate is obtained directly through the diet or indirectly via
elongation and desaturation of the essential omega-6 fatty acid precursor, linoleic acid (Guillou et al., 2010). Most synthesis of
arachidonate is thought to occur in the liver and is then distributed around the body complexed to albumin or esteriﬁed to
lipids and proteins. Thus, many cells in culture are expected to possess limited capacity to synthesise arachidonate and this,
combined with the degradation of linoleic and arachidonate through prolonged storage of serum, probably accounts for
arachidonate deﬁciency in most mammalian tissue culture.
The mechanisms that drive relative enrichment of C18:0 at the sn-1 and C20:4 at the sn-2 positions of phosphoinositides
are still poorly understood (Fig. 2B) (Anderson et al., 2013; D'Souza and Epand, 2014). There is evidence of signiﬁcant C38:4
selectivity in the conversion of DG species to both PA and CDP-DG destined for PI synthesis but there appears to be little acyl
selectivity in the subsequent conversions to PI (D'Souza and Epand, 2014, 2015). There is also good evidence that newly
synthesised PA and PI can undergo cycles of deacylation and reacylation catalysed by PLA1s, PLA2s and acyl-CoA-transferases
with substantial selectivity for their substrates e.g. LPIAT and LYCAT for incorporation of C20:4 and C18:0 into the sn-2 and sn-
1 positions of PI, respectively (Anderson et al., 2013; Imae et al., 2012; Lee et al., 2012). Our data showing very similar total
phosphoinositide pool sizes in the presence or absence of arachidonate supplementation suggest a combination of limited
Fig. 4. The effect of EGF on PIP3 accumulation in MCF10a cells grown in the presence or absence of arachidonate supplement. (A) Cells were incubated with or
without 14.8 mM arachidonate for 24 h (including 6 h starvation) before stimulation with 2 ng/ml EGF or vehicle for 90 s. Data is shown for each PIP3 species
corrected for amount of C36:1 phosphatidylserine in the same sample (mean ± SEM, n ¼ 3). Inset displays total combined species of PIP3 under each condition.
PIP3/PIP2 (B), PIP2/PI (C) and PIP/PI (D) ratios calculated from experiments described in panel A. Levels of PIP3 and PIP2 for C38:2 species under archidonate
loading conditions were too low to obtain accurate PIP3/PIP2 calculations and were thus omitted.
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the creation of different PI species to concentrate C38:4 species of phosphoinositides when appropriate fatty acids are
present, but ensure similar total levels of the these important lipids are created when they are limiting. Further, the similar
relative levels of different molecular species between steady-state pools of PI, PIP, PIP2 and PIP3, under both arachidonate
depleted and supplemented conditions, suggest that the kinases and phosphatases involved in their inter-conversion do not
exhibit profoundly different acyl selectivities with respect to the major species present (of note, C32:0 is a poor substrate for
PI4P5Ks (Shulga et al., 2012)).
Stimulation of starved MCF10a cells with EGF induced a very similar accumulation of total PIP3 species in both arach-
idonate limited or supplemented conditions. However, we did observe a signiﬁcant enrichment for some species of PIP3
compared to their corresponding levels of PIP2. This suggests that under conditions of acute Class I PI3K stimulation some
differential substrate selectivity/availability is revealed with respect to acyl chain composition for enzymes synthesising or
degrading PIP3 (ie Class I PI3Ks or phosphatases such as PTEN or SHIP1/2). It might be predicted that changes in nutrient
availability could affect the acyl composition of PIP3 and other phosphoinositides. Further, a recent study has argued that p53
mutational status can determine phosphoinositide acyl composition independent of culture conditions (Naguib et al., 2015).
Thus it will be important in future studies to understand how changes in the acyl composition of phosphoinositides might
affect their ability to act as regulatory molecules.
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